Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor

Philip Grant, Jonathan Taylor, Pat Cain, William Short, Joel Gallant, Charles Farthing, Gary Thal, Eoin Coakley, Andrew Zolopa

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

When fully suppressive regimens are not available, incompletely suppressive regimens also provide immunologic benefits. In this study, with stable background therapy, human immunodeficiency virus (HIV)-infected patients who were randomized to receive atazanavir or boosted atazanavir, compared with those who continued boosted protease inhibitor therapy, maintained similar virologic and immunologic control, resistance-mutation patterns, and replication capacities with reduced use of lipid-lowering medication.

Original languageEnglish (US)
Pages (from-to)680-682
Number of pages3
JournalClinical Infectious Diseases
Volume48
Issue number5
DOIs
StatePublished - Mar 1 2009

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)
  • Medicine(all)

Fingerprint

Dive into the research topics of 'Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor'. Together they form a unique fingerprint.

Cite this